Please assess the completion status of the following clinical trial:

Trial Title: Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Malignant conditions for which CD34+ selected, T-cell depleted allogeneic hematopoietic stem cell transplantation is indicated such as:~AML in 1st remission - for patients whose AML does not have 'good risk' cytogenetic features (i.e. t 8;21, t15;17, inv 16).~* Secondary AML in 1st remission~* AML in 1st relapse or \> 2nd remission~* ALL/LL in 1st remission clinical or molecular features indicating a high risk for relapse; or ALL \> 2nd remission~* CML failing to respond to or not tolerating Imatinib, dasatinib, or nilotinib in first chronic phase of disease; or CML in accelerated phase or second chronic phase.~* Non-Hodgkins lymphoma with chemoresponsive disease in any of the following categories: a) intermediate or high grade lymphomas who have failed to achieve a first CR or have relapsed following a 1st remission who are not candidates for autologous transplants.~* any NHL in remission which is considered not curable with chemotherapy alone and not eligible/appropriate for autologous transplant. Myelodysplastic syndrome (MDS): RA/RCMD with high risk cytogenetic features or transfusion dependence, RAEB-1 and RAEB-2 and Acute myelogenous leukemia (AML) evolved from MDS, who are not eligible for transplantation under protocol IRB 08-008.~* Chronic myelomonocytic leukemia: CMML-1 and CMML-2.~* Other rare lethal disorders of Hematopoiesis and Lymphopoiesis for which a T-cell depleted transplant is indicated (e.g. hemophagocytic lymphohistiocytosis; refractory aplastic anemia or conjugated cytopenias; non-SCID lethal genetic immunodeficiencies such as Wiskott Aldrich Syndrome, CD40 ligand deficiency, ALPS).~* Patients may be of either gender and of any racial or ethnic background.~* Patients must have a Karnofsky (adult) or Lansky (pediatric) Performance Status \> 70%.~* Patients must have adequate organ function measured by:~Cardiac: asymptomatic or if symptomatic then LVEF at rest must be \> 50% and must improve with exercise.~* Hepatic: \< 3x ULN ALT and \< 2.0x ULN total serum bilirubin, unless there is congenital benign hyperbilirubinemia.~* Renal: serum creatinine \<1.2 mg/dl or if serum creatinine is outside the normal range, then CrCl \> 40 ml/min (measured or calculated/estimated)~* Pulmonary: asymptomatic or if symptomatic, DLCO \> 50% of predicted (corrected for hemoglobin)~* Each patient must be willing to participate as a research subject and must sign an informed consent form.~Exclusion Criteria:~* Female patients who are pregnant or breast-feeding~* Uncontrolled viral, bacterial or fungal infection~* Patient seropositive for HIV-I/II; HTLV -I/II~* Presence of leukemia in the CNS.~Donor Inclusion Criteria:~* Each donor must meet criteria outlined by institutional policies~* Donor must have adequate peripheral venous catheter access for leukapheresis or must agree to placement of a central catheter.~Donor Exclusion Criteria:~* Evidence of active infection (including urinary tract infection, or upper respiratory tract infection), viral hepatitis exposure (on screening), unless only HBS Ab+ and HBV DNA negative, or serologic evidence of exposure or infection with HIV-I/II or HTLV-I/II~* If donors do not meet institutional guidelines, exclusion will be considered.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- REGIMEN 1 (Type: EXPERIMENTAL): REGIMEN 1: Patients undergo hyperfractionated TBI TID for a total of 11-12 doses on days -10 to -7 and receive thiotepa IV over 4 hours QD on days -6 and -5, fludarabine phosphate IV over 30 minutes QD on days -6 to -2, and anti-thymocyte globulin IV on days -4 to -2.~TRANSPLANTATION: Patients undergo CD34-selected allogeneic PBSCT on day 0.
- Regimen 2 (Type: EXPERIMENTAL): To be given to patients non-malignant, life-threatening diseases and patients with hematologic malignancies, with extensive prior therapy and comorbidities who are unable to receive TBI, consists of Melphalan 70mg/m2 IV x 2 days, thiotepa 5mg/kg IV x 2 days (or 10mg/kg x 1 day), and fludarabine 25 mg/m2 IV x 5 days.~TRANSPLANTATION: Patients undergo CD34-selected allogeneic PBSCT on day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).